U.S. markets closed
  • S&P Futures

    3,836.25
    +17.00 (+0.45%)
     
  • Dow Futures

    31,904.00
    +128.00 (+0.40%)
     
  • Nasdaq Futures

    12,386.50
    +89.25 (+0.73%)
     
  • Russell 2000 Futures

    2,208.40
    +7.60 (+0.35%)
     
  • Crude Oil

    65.37
    +0.32 (+0.49%)
     
  • Gold

    1,683.70
    +5.70 (+0.34%)
     
  • Silver

    25.28
    +0.02 (+0.06%)
     
  • EUR/USD

    1.1853
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    1.5960
    +0.0420 (+2.70%)
     
  • Vix

    25.47
    +0.81 (+3.28%)
     
  • GBP/USD

    1.3828
    +0.0006 (+0.04%)
     
  • USD/JPY

    109.1740
    +0.2730 (+0.25%)
     
  • BTC-USD

    53,618.15
    +2,081.28 (+4.04%)
     
  • CMC Crypto 200

    1,082.43
    +58.22 (+5.68%)
     
  • FTSE 100

    6,719.13
    +88.61 (+1.34%)
     
  • Nikkei 225

    28,810.60
    +67.35 (+0.23%)
     

Bronstein, Gewirtz & Grossman, LLC Notifies Investors of scPharmaceuticals Inc. (SCPH) Investigation

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / December 8, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of scPharmaceuticals Inc. ("scPharmaceuticals" or "the Company") (NASDAQ:SCPH). Investors who purchased scPharmaceuticals securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/scph.

The investigation concerns whether scPharmaceuticals and certain of its officers and/or directors have violated federal securities laws.

On December 7, 2020, scPharmaceuticals issued a press release announcing receipt of a Complete Response Letter ("CRL") from the U.S. Food and Drug Administration ("FDA") on December 3, 2020 regarding the Company's New Drug Application ("NDA") for the Company's FUROSCIX product. The Company's press release stated that "[i]n the CRL, the FDA cited their need to conduct pre-approval inspections at two of the company's third-party manufacturing facilities that could not be conducted due to travel restrictions. In addition, the FDA raised questions related to testing, labeling, and features of the combination product unrelated to the drug constituent. In addition, the FDA indicated that there were deficiencies at the third-party facility where the Company's off-the-shelf alcohol swabs are manufactured." On this news, scPharmaceuticals' stock price fell $3.11 per share, or 35.58%, to close at $5.63 per share on December 7, 2020.

If you are aware of any facts relating to this investigation, or purchased scPharmaceuticals shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/scph. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/620014/Bronstein-Gewirtz-Grossman-LLC-Notifies-Investors-of-scPharmaceuticals-Inc-SCPH-Investigation